Mature B-Cell Lymphoma And Leukemia Study III

[...] er limit of normal (ULN), and/or bone marrow/CNS involvement. : All participants who will receive rituximab must have hepatitis screening prior to en [...] ation Yes or No) HBsAg Anti-HBs antibody Anti-HBc antibody. All participants must have screening prior to enrollment; participants whose results indicate that they are carrier of hepatitis B can still be treated per group B and C but will NOT receive rituximab HIV test has been obtained within 42 days. Participants who [...]

Gene differential profiling of BurkittsBurkitt Lymphoma (BL) vs. non-BL

[...] rathecal chemotherapy treatment, and/or emergency radiation). Participant must be < 22 years of age at the time of diagnosis For selected higher-risk CD20+ Group B and all CD20+ Group C participants receiving rituximab only (e.g., those with MLB [...] are carrier of hepatitis B can still be treated per Group B or C but will NOT receive rituximab. This screening must be done for eligibility for participants who will receive rituximab, BUT the results are not needed prior to enrollment: Hepatit [...] ccording to St. Jude guidelines before enrollment into study. Participants from Collaborating Sites Participat [...] [...]

Inclusion Criteria: St. Jude Participantsparticipants and collaborating sites participating in therapeutic and biological objectives: Participant must have a histologic diagnosis of a mature B [...] be previously untreated, (no more than 72 hours of steroids, one intrathecal chemotherapy treatment, and/or emergency radiation) Participant must be < 22 years of age at the time of diagnosis For selected higher-risk Group B participants withreceiving mediastinal large B cell lymphoma (MLBCL) diseaserituximab only (receivinge.g., rituximabthose with MLBLC, Stage III with LDH ≥ 2 times upper limit of norm [...] [...]

This study will perform transcriptional profiling and genome-wide analysis of DNA copy number abnormalities and loss-of-heterozygosity using DNA microarrays in children with newly diagnosed diffuse largemature B-cell lymphomas (e.g. Burkitt lymphoma/leukemia, DLBCL), and smallMLBCL) non-cleaved lymphomasobtained from participants in different parts of the world. This study will describe the [...] and frequency of mutations in the ARF-HDM2-TP53 pathway, in "non-endemic" B-cell lymphomas (in the United States) and thosethat found in selected geographic regions of the world. This stu [...] -HDM2-TP53 and PUMA [...]

Complete response rate, event Event-free survival Overall andSurvival Percentage overallof survivalparticipants who complete therapy with the use of rituximab Number of possible rituximab-related toxicities

ToCatalog describeand theestimate expressionfrequencies of ARFcopy number variations in childhood lymphomas Gene differential profiling of Burkitts Lymphoma (BL) vs. non-HDM2-TP53BL Integrated analysis of CNVs and PUMA-associatedgene pathways in B-cell lymphomas in the United States and that found in B-cell lymphomas of other selected geographic regions of the worldexpressions To describe the patternPattern and frequency of XLP gene mutations presenting with B-cell [...] mphomas in the United States and selected geographic regions. To describe the patternPattern of EBV protein expression (e.g., EBNA [...] [...]

[...] cell lymphoma (MLBCL) disease only (receiving rituximab) - HepatitisAll participants with MLBCL assigned to Group B must have hepatitis screening hasprior beento obtainedenrollment. Participants whose results indicate that they are carrier of hepatitis B can still be treated per Group B but will NOT receive rituximab. This screening must be done for eligibility BUT the results [...]

[...] steroids and/or emergency radiation) Participant must be < 2122 years of age at the time of diagnosis For Group B participa [...] as defined in the WHO classification Participant must be < or = to 2122 years of age at the time of diagnosis Informed consent must [...] ives: Participants with prior therapy (except steroids or RT as described in 3.1.1) Participants known to be HIV positive (for therapeutic par [...]

ThisComplete studyresponse willrate, includeevent-free the study of acutesurvival and lateoverall effects of this treatment on the central nervous system, bone mineral density, fertility, and cardiac system.survival

[...] and those found in selected geographic regions of the world (Brazil, Chile, Guatemala, Honduras, El-Salvador, Singapore and others). This study will describe the expression of ARF-HDM2-TP53 and PUMA-associated pathways in non-endemic B-cell lymphomas (United States) and that found in B-cell lymphomas of other selected geographic regions of the world (see above). This study will describe the pattern and frequency of XLP gene mutations in boys presenting with B-cell lymphomas in the United States and s [...] gene expression with clinical, laboratory and outcome data. ThisSecondary studyObjective: To w [...] [...]

[...] tinal large B cell lymphoma (MLBCL) disease only (receiving rituxumabrituximab) - Hepatitis screening has been obtained. This screening mu [...] ination Yes or No) HBsAg Anti-HBs antibody Anti-HBc antibody. All participants must have screening prior to enrollment. Pa [...] till be treated per Group B but will NOT receive rituximab. HIV test has been obtained within 42 days. Participants who test positive for HIV cannot be enrolled on therapeutic part of study, but are still eligible for biology studies. Informed consent must be obtained according to St. Jude guidelines before enrollment into study Non-Parti [...] [...]

[...] of the world: and will describe the pattern of EBV protein and gene expression (e.g., EBNA 3) in EBV-positive lymphomas and the study will compare patterns of EBV protein and gene expression with clinical, laboratory and outcome data. This [...]

[...] as described in 3.1.1) Participants known to be HIV positive(for therapeutic part of protocol, HIV participants are eligible for biology studies). Participants who are pregnant or lactating Inability or unw [...]